12:00 AM
 | 
Apr 25, 2011
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Neogenix Oncology preclinical data

In mouse xenograft models of solid tumors, NEO-201 significantly reduced tumor growth vs. a control IgG antibody (p=0.0034). NEO-201 is...

Read the full 77 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >